MK-8033 treatment reduced MET phosphorylation in wild-type uveal melanoma cells and GNAQ mutant cells by relatively similar proportions compared with baseline. Incubation with MK-8033 produced strong antiproliferative effects against a panel of OVCA cell lines. In a human cathepsin L assay, the reported IC50 was <0.5 nM. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Reduced MET phosphorylation in wild-type uveal melanoma cells
Cell-based study · WT uveal melanoma cells (MEL290) [1]
MK-8033 treatment reduced MET phosphorylation in WT uveal melanoma cells (MEL290) relative to baseline.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 1 and 2.5 µM
- Vehicle
- dimethyl sulfoxide (DMSO)
- Reported limits
- Not stated in the sentences used: route, schedule.
Methods and source locations
Compound reported in the paper: MK-8033
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Reagents (S4); Results > Effect of MEKi and/or METi Treatment on MET and Erk1/2 Phosphorylation in Uveal Melanoma Cells (S51, S52); Figure 2 legend (S84)
MET phosphorylation: MET phosphorylation; comparator: baseline MET phosphorylation levels — Results > Effect of MEKi and/or METi Treatment on MET and Erk1/2 Phosphorylation in Uveal Melanoma Cells (S51, S52); Figure 2 legend (S84)
Antiproliferative effects in OVCA cell lines
Cell-based study · a panel of OVCA cell lines [2]
Incubation of a panel of OVCA cell lines with MK-8033 produced strong antiproliferative effects.
Literature-Reported Treatment Conditions
- Exposure duration
- 72-h incubation
- Method
- incubation with MK8033
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: MK-8033
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Cell viability assays (S25); Results > Inhibition of HGF/c-Met signaling has in vitro anti-proliferative effects on OVCA cells and synergizes with combination carboplatin plus paclitaxel (S45); Figure 1 legend (S51)
percent OVCA cell viability: percent OVCA cell viability; comparator: untreated cells — Results > Inhibition of HGF/c-Met signaling has in vitro anti-proliferative effects on OVCA cells and synergizes with combination carboplatin plus paclitaxel (S45); Figure 1 legend (S51)
Human cathepsin L inhibition
Cell-based study · human cathepsin L [3]
Against human cathepsin L, the compound had an IC50 of <0.5 nM.
Literature-Reported Treatment Conditions
- Reported limits
- Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: MK-8033; Compound label in the paper: CPD 11R
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > SARS-CoV-2 3CLpro and human cathepsin L biochemical assays (S1); Table 1 (T1.r1, T1.r2)
Cathepsin L IC50 (nM): Cathepsin L IC50 (nM) — Table 1 (T1.r2)
Reduced MET phosphorylation in GNAQ mutant cells
Cell-based study · GNAQ mutant cells (MEL202) [1]
MK-8033 treatment reduced MET phosphorylation in GNAQ mutant cells (MEL202) relative to baseline, by a relatively similar proportion to that observed in wild-type cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 1 and 2.5 µM
- Vehicle
- dimethyl sulfoxide (DMSO)
- Reported limits
- Not stated in the sentences used: route, schedule.
Methods and source locations
Compound reported in the paper: MK-8033
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Reagents (S4); Results > Effect of MEKi and/or METi Treatment on MET and Erk1/2 Phosphorylation in Uveal Melanoma Cells (S51, S52); Figure 2 legend (S84)
MET phosphorylation: MET phosphorylation; comparator: baseline MET phosphorylation levels — Results > Effect of MEKi and/or METi Treatment on MET and Erk1/2 Phosphorylation in Uveal Melanoma Cells (S51, S52); Figure 2 legend (S84)